**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 59432

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Prevalence and risk factors of nonalcoholic fatty liver disease in patients with inflammatory bowel diseases: A cross-sectional and longitudinal analysis**

Hoffmann P *et al.* Nonalcoholic fatty liver disease in IBD

Peter Hoffmann, Victoria Jung, Rouven Behnisch, Annika Gauss

**Peter Hoffmann, Victoria Jung, Annika Gauss,** Department of Gastroenterology and Hepatology, University Hospital Heidelberg, Heidelberg 69120, Germany

**Rouven Behnisch,** Institute of Medical Biometry and Informatics, University Hospital Heidelberg, Heidelberg 69120, Germany

**Author contributions:** Hoffmann P provided medical data, analyzed the data and drafted the manuscript;Jung V collected the data from medical records and analyzed the data; Gaus A helped with the study design, provided medical data and drafted the manuscript; Behnisch R analyzed the data; all authors read and approved the final version of the manuscript.

**Corresponding author: Peter Hoffmann, MD, Doctor,** Department of Gastroenterology and Hepatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, Heidelberg 69120, Germany. peter.hoffmann@med.uni-heidelberg.de

**Received:** October 12, 2020

**Revised:** November 3, 2020

**Accepted:** November 21, 2020

**Published online:** December 14, 2020

**Abstract**

BACKGROUND

Nonalcoholic fatty liver disease (NAFLD) is common in the German population, with an even higher prevalence in inflammatory bowel disease patients.

AIM

To investigate the risk factors for NAFLD in inflammatory bowel disease patients.

METHODS

This monocentric retrospective study with a cross-sectional and a longitudinal part included 694 patients. Inclusion criteria were diagnosed inflammatory bowel disease, age ≥ 18 years, availability of at least one abdominal ultrasound. Patients with infectious or suspected alcoholic fatty liver disease were excluded. NAFLD was defined by increased echogenicity at liver ultrasound. Demographic characteristics, disease activity and medications were analyzed as potential risk factors. Parameters influencing the course of NAFLD were identified by a generalized linear mixed model.

RESULTS

Forty-eight percent of Crohn’s disease (CD) patients and 44% of ulcerative colitis patients suffered from NAFLD. Its occurrence was associated with greater age, hypertension and body mass index (BMI) in both groups, and with higher disease activity and dyslipidemia in CD. 2467 ultrasound results were included in the longitudinal analysis. Risk factors for NAFLD were age, BMI, higher disease activity, bowel resection(s), endoscopic activity and azathioprine use in CD; and BMI and endoscopic activity in ulcerative colitis.

CONCLUSION

NAFLD was highly prevalent in this cohort of German inflammatory bowel disease patients. Its risk increased mainly with rising age and BMI. This analysis provides a rationale for non-invasive liver screening in inflammatory bowel disease patients.

**Key Words:** Crohn’s disease; Ulcerative colitis; Inflammatory bowel disease; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Ultrasound

**Citation:** Hoffmann P, Jung V, Behnisch R, Gauss A. Prevalence and risk factors of nonalcoholic fatty liver disease in patients with inflammatory bowel diseases: A cross-sectional and longitudinal analysis. *World J Gastroenterol* 2020; 26(46): 7367-7381

**URL:** https://www.wjgnet.com/1007-9327/full/v26/i46/7367.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v26.i46.7367

**Core Tip:** Nonalcoholic fatty liver disease (NAFLD) has a high prevalence. Aim is to investigate risk factors for NAFLD in inflammatory bowel disease. 48% of Crohn’s disease (CD) and 44% of ulcerative colitis patients suffered from NAFLD. Its occurrence was associated with greater age and body mass index (BMI) in both groups, and with higher disease activity in CD. Risk factors for NAFLD in the longitudinal analysis were age, BMI, higher disease activity, bowel resection(s), endoscopic activity and azathioprine use in CD; and BMI and endoscopic activity in ulcerative colitis.

**INTRODUCTION**

Nonalcoholic fatty liver disease (NAFLD) is a common disorder with a prevalence of 25% worldwide[1] and 22.9% in the German population. Its prevalence in Germany is expected to reach 26.4% by the year 2030[2]. In patients with inflammatory bowel diseases (IBDs) – consisting of Crohn’s disease (CD) and ulcerative colitis (UC) – an even higher NAFLD prevalence of up to 40% has been described[3-5].

The main risk factor for NAFLD is the metabolic syndrome[6]. Ultrasound of the liver is the most common diagnostic tool to detect NAFLD with a sensitivity of 85% and specificity of 94%[7]. Hepatic steatosis may progress to nonalcoholic steatohepatitis (NASH), which can result in the development of cirrhosis and hepatocellular carcinoma. NAFLD is associated with an increased overall mortality and independently predicts the risk for future cardiovascular disease events[8,9].

IBD patients develop NAFLD based on fewer metabolic risk factors in comparison with non-IBD NAFLD patients[10]. In IBD patients, hypertension, obesity, small bowel surgery, and use of corticosteroids at the time of imaging were associated with NAFLD, while among patients receiving anti-TNFα therapy, NAFLD has been shown to be less prevalent[10]. In contrast, another study found a high prevalence of NAFLD among IBD patients under anti-TNFα treatment[11].

Thus it may be assumed that the risk factors for NAFLD in IBD patients differ from those in the general population. Even underweight IBD patients showed an increased prevalence of NAFLD[12]. A history of bowel resection(s) and parenteral nutrition have also been described as risk factors for NAFLD[13,14]. Treatment with high doses of corticosteroids–as still frequently applied in IBD patients–has been related to hepatic steatosis as well[15].

The key goal of this study was to investigate the prevalence and risk factors of NAFLD in patients suffering from IBD. The superordinate aim of this project is to optimize preventive and therapeutic measures of NAFLD in the identified population at risk, and thus to reduce the incidence of NASH or hepatocellular carcinoma in IBD patients.

**MATERIALS AND METHODS**

***Study design and data extraction***

This is an uncontrolled, monocentric retrospective study including patients diagnosed with IBD at a South German tertiary referral center for the care of IBD. The Ethics Committee of the University of Heidelberg (protocol number: S-299/2018) approved the study. Inclusion criteria were as follows: (1) age ≥ 18 years; (2) diagnosis of IBD according to European Crohn’s and Colitis Organisation criteria[16]; (3) therapy at the IBD outpatient clinic of the University Hospital Heidelberg; (4) at minimum one visit to the IBD outpatient department between June 1, 2014 and May 31, 2018; and (5) availability of at least one documented abdominal ultrasound examination including profound assessment of the liver performed prior to May 31, 2018, as this date was defined as the cut-off time point for data acquisition. Exclusion criteria were: (1) diagnosis of any infectious liver disease; (2) suspected alcoholic fatty liver disease; or (3) documented abuse of alcohol (daily intake of alcohol of > 10 g/d in women and > 20 g/d in men). All data were collected from computerized medical course records. The available daily consultation lists of the IBD outpatient clinic between June 1, 2014 and May 31, 2018 were screened, to identify eligible patients.

All data concerning NALFD diagnosis and grading of NAFLD severity were extracted from the liver ultrasound reports of the patients. NAFLD severity was categorized into four groups: (1) no steatosis; (2) mild steatosis; (3) moderate steatosis; and (4) severe steatosis, as specified in the ultrasound report.

Demographic and disease-related parameters of all included patients were entered into a Microsoft Excel spreadsheet. As standard at the IBD outpatient department, all IBD patients who were under immunosuppressive treatment underwent a routine abdominal ultrasound every year. Patients who visited the clinic for the sole purpose of a second opinion usually did not receive an abdominal ultrasound examination. In cases of diagnosed NALFD, the patients were routinely advised about lifestyle modifications, including nutrition and physical training.

***Definitions***

The Montreal classification for CD and UC[17] was used to categorize disease extent. Disease activity was graded using the Harvey Bradshaw Index (HBI)[18] for CD patients and the Simple Clinical Colitis Activity Index (SCCAI)[19] for UC patients. A HBI and SCCAI of > 4, respectively, were considered to represent active inflammation. HBI and SCCAI scores have been routinely used at our outpatient clinic since 2017 to monitor disease activity and evaluate therapeutic effects. For data collected prior to 2017, the indices were retrospectively calculated on the basis of all written information available in the patients’ records.

Studied variables included age at diagnosis of IBD, age at index abdominal ultrasound, body mass index (BMI), sex, presence of diabetes mellitus, dyslipidemia or hypertension, smoking status, CD location and phenotype, extent of UC, laboratory results [plasma concentrations of aspartate aminotransferase, alanine aminotransferase, gamma-glutamyltransferase (γGT), C-reactive protein, white blood cell count, fecal calprotectin concentration], HBI, SCCAI, inflammation detected by intestinal ultrasound or colonoscopy, medications, history of intestinal surgery, parenteral nutrition, concomitant diseases, and infections.

A sonographically measured bowel wall thickness of > 3 mm in the small bowel and of > 4 mm in the colon were considered to represent inflammation. Endoscopically active disease was considered whenever the mucosa was not described as normal.

***Liver ultrasound***

In the cross-sectional component of this study, ultrasound results from May 31, 2017 through May 31, 2018 were included. In the longitudinal part of the study, all results of any ultrasound examination ever performed at our center in the included patients were considered.

***Study endpoints***

The primary study end points were (1) to determine the prevalence of NAFLD in the cross-sectional part of the study; (2) to reveal factors associated with changes of the presence and severity of NAFLD during the further disease course in the longitudinal part of the study.

The secondary aim of the study was to identify potential risk factors for NAFLD in the cross-sectional component of the study.

***Statistical analyses***

All statistical analyses were performed using “R” Version 3.5.2 (2018-12-20). Normality of data distribution was first assessed using the Shapiro-Wilk test. None of the data were normally distributed, so the results were calculated as medians and interquartile ranges.

To identify potential risk factors for NAFLD, the Mann-Whitney-*U*-test and Kruskal-Wallis-test were used for ordinal and continuous variables, and *x*²-tests for categorical variables. For the multivariable assessment of risk factors for NAFLD, a logistic regression analysis was performed. A backwards elimination was used with the following parameters: BMI, age, sex, diabetes mellitus, hypertension, current smoking, dyslipidemia, activity index showing inflammation (HBI and SCCAI), elevated C-reactive protein level, inflammation in colonoscopy, previous bowel resection(s), as well as therapy with steroids, azathioprine, infliximab, adalimumab, vedolizumab, ustekinumab, mesalazine or sulfasalazine. A linear mixed model for repeated measurements was applied for the identification of potential risk factors which influence the changes in NAFLD: the change of NAFLD status was the dependent variable, while the previously identified and known confounders of BMI, age, sex, diabetes mellitus, hypertension, dyslipidemia, current smoking, and use of steroids were fixed factors. Parameter estimates were determined together with 95% confidence intervals and associated *P* values.

In the linear mixed model for repeated measurements, all ultrasound examinations were included. The model considered the different numbers of ultrasound examinations per patient as well as changes in clinical, laboratory and treatment parameters and their impact on NAFLD. Because of the exploratory character of the study, there was no adjustment for multiple testing. The interpretation of *P* values is descriptive. *P* values < 0.05 were considered as statistically significant.

**RESULTS**

***Characteristics of Crohn’s disease patients***

651 different CD patients attended the IBD outpatient clinic between June 1, 2014 and May 31, 2018. Among these, 184 patients did not undergo any ultrasound examination, which was mainly due to their receiving a second opinion for therapy of CD. Exclusion of 22 patients was due to the diagnosis of other liver diseases, and five patients due to alcohol abuse. Thus, 440 CD patients who underwent at least one abdominal ultrasound examination were included. Among these 440 patients, 138 patients were excluded from the cross-sectional part of the study because they did not undergo any ultrasound examination between May 31, 2017 and May 31, 2018, leaving 302 patients included in the cross-sectional part of the study. In the longitudinal part of the study, 1620 abdominal ultrasound results from 440 patients were included. Figure 1A shows a flow diagram of all patient inclusions and exclusions.

Forty-nine percent of the included CD patients in the cross-sectional study were male, the median age at the time of the ultrasound examination was 42 years, and the median BMI was 24.5 kg/m².

***Results of the cross-sectional study in CD patients***

In the cross-sectional study, fifty-two percent of the CD patients did not suffer from NAFLD. Mild NAFLD was revealed in 18%, moderate NAFLD in 16%, and severe NAFLD in 14% of the patients.

Comparison of demographic and disease-related parameters between the subgroups with and without a diagnosis of NAFLD determined by the ultrasound results is shown in Table 1.

The BMI differed significantly between the subgroups: 23.0 kg/m² was the median BMI of patients without NAFLD as compared to 28.0 kg/m² in patients with NAFLD (*P* < 0.001). Age at abdominal ultrasound was 35 years in patients without NAFLD as compared to 49 years in patients with NAFLD (*P* < 0.001). An increased HBI > 4 was found in 15% of the patients without NAFLD, compared to 40% with NAFLD (*P* < 0.001). Other significant differences were revealed in dyslipidemia, hypertension, γGT, disease duration, history of bowel resection(s), and treatment with sulfasalazine. Laboratory results and endoscopic or ultrasound results suggesting active inflammation were not associated with the presence of NAFLD, while elevated plasma liver enzyme concentrations tended to be more frequent in NAFLD patients (*P* = 0.069).

Using a multivariable logistic regression model, age at abdominal ultrasound, increased HBI, and increased BMI were identified as independent risk factors for NAFLD in CD patients (Table 2).

Using a multivariable logistic regression model considering BMI and disease duration, disease duration was also significantly associated with NAFLD (*P* < 0.001). These results were evaluated in a separate model, as age and disease duration are too similar to be included in the same model.

***Time-dependent course of NAFLD and relation to CD therapy***

In the 440 included CD patients, 1620 abdominal ultrasound examinations were performed (Figure 1A). The minimum number of examinations per patient was one, while the maximum number of examinations per patient was 12 (Table 3). Of 1180 time intervals, a NAFLD improvement was found in 141 time intervals (11.9%), while NAFLD deteriorated in 159 intervals (13.5%), 880 time intervals showed no change (74.6%). The mean length of a time interval was three years and seven months. Using a linear mixed model for repeated measurements, the parameters at the time intervals between the ultrasound examinations were inspected. In Table 4,the results of the linear mixed model for repeated measurements analyzing the NAFLD status are shown.

First, potential confounders as BMI, age, sex, diabetes mellitus, hypertension, dyslipidemia, current smoking, and steroid use were included in the model. BMI [Odds Ratio (OR): 1.32, *P* < 0.001] age (OR: 1.07, *P* < 0.001) and dyslipidemia (OR: 10.82, *P* = 0.049) were statistically associated with progression of NAFLD. In a second step, an additional linear mixed model including all parameters plus BMI and age was calculated. Increased HBI, inflammation in colonoscopy, history of bowel resection(s), and azathioprine use were significantly associated with NAFLD progression.

***Characteristics of ulcerative colitis patients***

400 different UC patients attended the IBD outpatient department between June 1, 2014 and May 31, 2018. Of these, 128 patients suffering from UC did not undergo any ultrasound examination at our clinic mainly due to the fact that they came to receive a second opinion. Sixteen patients were excluded due to other liver diseases, and two patients due to alcohol abuse. Thus, 254 patients who underwent more than one abdominal ultrasound examination at the IBD outpatient clinic were included in the study. Of these 254 patients, 101 patients were excluded from the cross-sectional part of the study because they did not undergo any ultrasound examination between May 31, 2017 and May 31, 2018. Thus, 153 patients were included in the cross-sectional part of the study. In the longitudinal part of the study, 847 abdominal ultrasound results from 254 patients were considered. Figure 1B shows a flow diagram of inclusions and exclusions for all UC patients.

Fifty percent of the UC patients included in the cross-sectional part of the study were male, the median age at the time point of ultrasound was 40 years, while the median BMI was 25.4 kg/m².

***Results of the cross-sectional study in UC patients***

In the cross-sectional study, fifty-six percent of the included UC patients showed no signs of NAFLD, while mild NAFLD was diagnosed in 20%, moderate NAFLD in 16%, and severe NAFLD in 8%.

Demographic and clinical parameters were compared between the patients who were diagnosed with NAFLD and those who were not. Table 5 demonstrates the differences of demographic and clinical parameters of patients with NAFLD compared to patients without NAFLD.

The BMI diverged significantly between patients with NAFLD and those without: patients without NAFLD had a median BMI of 22.8 kg/m² as compared to 28.0 kg/m² in patients with NAFLD (*P* < 0.001). Age at abdominal ultrasound was 37.0 years in patients without NAFLD as compared to 48.5 years in patients with NAFLD (*P* = 0.005). In patients with NAFLD, hypertension and smoking in genereal were more common compared to patients without NAFLD (*P* < 0.001). An SCCAI > 4 was found in 14% of the patients without NAFLD as compared to 24% in those with NAFLD (*P* = 0.156). Another significant difference was revealed in plasma γGT concentrations, which were 23 U/L in NAFLD patients and 18 U/L in patients without NALFD (*P* = 0.007). There was no association of laboratory results as well as endoscopic or ultrasound results proving inflammation with the occurrence of NAFLD.

Making use of a multivariable logistic regression model, increased BMI was identified as the only independent risk factor for NAFLD in UC patients (Table 6).

A multivariable logistic regression model considering BMI and disease duration did not identify disease duration as a risk factor of NAFLD in UC patients (*P* = 0.066).

***Time-dependent course of NAFLD and relation to UC therapy***

In the cohort of the 253 UC patents, 847 ultrasound examinations were performed in total (Figure 1B). The minimum number of examinations per patient was one, while the maximum number of examinations per patient was 12 (Table 3). In 593 time intervals, NAFLD improved over 77 time intervals (13.0%), while it worsened over 72 intervals (12.1%), and 444 time intervals showed no change (74.9%). The mean length of a time interval was three years and nine months. A linear mixed model for repeated measurements analyzing NAFLD change over time showed the results summarized in Table 7.

In a first step, the potential confounders BMI, age, sex, diabetes mellitus, hypertension, dyslipidemia, current smoking, and steroid use were included in the model. BMI and hypertension were statistically associated with progression of NAFLD (OR: 1.28, *P* < 0.001; OR: 2.89, *P* = 0.037), while age was not (OR: 1.01, *P* = 0.667). In a second step, a linear mixed model including all the different parameters plus BMI and age was calculated. Significant associations were revealed between progression of NAFLD and endoscopically detected inflammation.

**DISCUSSION**

Our study is one of the first large retrospective studies also including longitudinal analyses to explore changes of NAFLD severity during the course of IBD in up to 18 years of follow-up. As key findings, we confirmed that higher BMI and age are risk factors for the development of NAFLD in IBD patients, while clinical disease activity as expressed by higher HBI scores proved to be another independent risk factor in CD patients.

In patients with steatosis of > 33% of hepatocytes, liver ultrasound is a very reliable tool to detect steatosis. However, the method is not suitable to exclude mild fatty infiltration of the liver[20]. Therefore, we are aware that our results may underestimate the prevalence of NAFLD.

In the cross-sectional part of the study, 157 (52%) of the CD patients had no NAFLD, while mild NAFLD was diagnosed in 54 (18%), moderate NAFLD in 50 (16%), and severe NAFLD in 41 (14%) of the patients. In UC patients, corresponding results were 85 (56%), 30 (20%), 25 (16%), and 13 (8%).

In the longitudinal part of this study, 2467 hepatic ultrasound results were included. Age, dyslipidemia and BMI in CD patients and BMI and hypertension in UC patients were identified as risk factors in the mixed logistic regression model. Also, in CD patients, higher HBI, endoscopic disease activity, history of bowel resection(s), and use of azathioprine were risk factors for NAFLD. In UC patients, endoscopic disease activity was significantly associated with NAFLD in the mixed logistic regression model.

In a recent smaller cohort of Greek IBD patients, NAFLD was revealed in 14.2% of the included CD patients and in 26.2% of the included UC patients[21]. In comparison, our data identify a higher prevalence of NAFLD in both patient groups. The same is the case if we compare our results with those of Bargiggia *et al*[3] from 2003. Concerning the Greek study, the discrepancy might be explained by diverging dietary habits. Looking at the study by Bargiggia *et al*[3], it should be noted that nutrition has relevantly changed over the last 15 years. One more important factor to bear in mind is the improvement of IBD therapies and thus the better management of malnutrition in IBD patients over time.

A recently published meta-analysis included one study from Japan and 18 studies from Western countries: it found an overall prevalence of NAFLD in 27.5% of IBD patients and identified type 2 diabetes, hypertension, obesity, insulin resistance, metabolic syndrome, chronic kidney disease, methotrexate use, surgery for IBD, and longer duration of IBD as risk factors for its development[22].

We also identified greater age in CD patients as a risk factor for NAFLD. This finding may be due to a higher prevalence of metabolic risk factors with rising age.

In Germany, the mean BMI in the general population in the year 2013 was 26.5 kg/m² in females and 27.2 kg/m² in males[23]. Median BMI in our study as compared to the mean BMI in Germany was lower: 25.5 kg/m² in CD patients and 25.7 kg/m² in UC patients. That is why higher BMI alone cannot explain the high prevalence of NAFLD in our IBD patients. Furthermore, metabolic syndrome was only diagnosed in 23% of IBD patients in the United States[24].

In contrast to the results of the above-cited meta-analysis, we found in our cohort no association between methotrexate use and NAFLD, but between azathioprine use and an increase of NAFLD severity (OR: 1.98). In our cohort, azathioprine was prescribed far more frequently than methotrexate. All other drug therapies of IBD including corticosteroids were not associated with the course of NAFLD in our patients. Interestingly, in contrast, a study from 2013 identified corticosteroids as potential risk factor for NAFLD[10], while a more recent study showed no difference of steroid use in NAFLD and non-NAFLD IBD patients[25].

The positive correlation of clinical and endoscopic disease activity with NAFLD deterioration in the longitudinal part of the study leads us to the assumption that the systemic, extraintestinal inflammation caused by IBD may promote the development of NAFLD. Also, a history of bowel resection(s) resulted in a progression of NAFLD over time. This observation supports the hypothesis that bowel inflammation may aggravate NAFLD, as surgery is usually performed in patients with aggressive disease courses.

Adipokines also play a role in intestinal inflammation[26]. There may be a link between visceral fatty tissue, NALFD and intestinal inflammation, all factors influencing one another in a detrimental way. For example, apelin is upregulated in the intestinal epithelial cells of IBD patients and highly expressed in the mesenteric adipose tissue of Crohn’s disease patients[27,28]. Another study group showed that apelin is promoting hepatic fibrosis[29].

There are several limitations of the study. Due to its retrospective, uncontrolled nature, risk of bias is given. We focused on patients visiting a university IBD outpatient clinic. 184 CD and 128 UC patients did not undergo any abdominal ultrasound examination due to only getting a second opinion, which may produce a selection bias. Patients who did not receive immunosuppressive therapy did not undergo routine ultrasound examinations as well. Another limitation is the examiner dependency of the ultrasound examination results. Further limitations are that vibration controlled transient elastography or MR spectroscopy were not routinely performed to grade steatosis and fibrosis; nor was liver histology examined. Differentiation between NAFLD and NASH is only possible by histology. Also, nothing is known about the nutrition or the exact metabolic status of the patients. However, elevated plasma γGT concentrations and the tendency of elevated transaminases in CD patients in our study support the correct discrimination of NAFLD by liver ultrasound.

One of the strengths of our study is the multitude of liver ultrasound examinations performed over a long duration. Thus, our study implies the possibility to reveal the influence of parallel therapies for IBD and the course of NAFLD under real-world conditions. Our data is relatively homogeneous, due to restriction to patients treated at a university center for IBD. In the cross-sectional component of our study, the data was retrieved exclusively from May 2017 until 2018, when data documentation at our center had been optimized by new standard operation procedures for the outpatient clinic.

**CONCLUSION**

We conclude from our results that NAFLD is very common in IBD patients, especially in older patients and patients with higher BMI. Disease activity and azathioprine use in CD may increase the prevalence of NAFLD. As visceral fat seems to perpetuate inflammation, IBD patients with NAFLD may be at risk of more aggressive IBD course, so they may require more intense anti-inflammatory treatment strategies. Our study provides a rationale for regular ultrasound screening of the liver in IBD patients. Further prospective studies are necessary to detect the role of disease activity and the influence of different medication in NAFLD in IBD patients.

**ARTICLE HIGHLIGHTS**

***Research background***

Nonalcoholic fatty liver disease (NAFLD) is common in the German population, with an even higher prevalence in inflammatory bowel disease patients.

***Research motivation***

Finding reasons for the high prevalence of NAFLD in inflammatory bowel disease patients.

***Research objectives***

Identifying risk factors for NAFLD in inflammatory bowel disease patients.

***Research methods***

Analysis of abdominal ultrasound examinations of inflammatory bowel disease patients and electronically available data was performed. Demographic characteristics, disease activity and medications were analyzed as potential risk factors in a cross-sectional design. Parameters influencing the course of NAFLD were identified by a generalized linear mixed model.

***Research results***

Forty-eight percent of Crohn’s disease (CD) patients and 44% of ulcerative colitis patients suffered from NAFLD. Its occurrence was associated with greater age, hypertension and body mass index (BMI) in both groups, and with higher disease activity and dyslipidemia in CD. 2467 ultrasound results were included in the longitudinal analysis. Risk factors for NAFLD were age, BMI, higher disease activity, bowel resection(s), endoscopic activity and azathioprine use in CD; and BMI and endoscopic activity in ulcerative colitis.

***Research conclusions***

This study shows that NAFLD is highly prevalent in a cohort of German inflammatory bowel disease patients. Its risk increased mainly with rising age and BMI. The analysis provides a rationale for non-invasive liver screening in inflammatory bowel disease patients.

***Research perspectives***

A randomized controlled prospective study is required to further verify the discovered risk factors.

**REFERENCES**

1 **Younossi ZM**, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology* 2016; **64**: 73-84 [PMID: 26707365 DOI: 10.1002/hep.28431]

2 **Estes C**, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, Colombo M, Craxi A, Crespo J, Day CP, Eguchi Y, Geier A, Kondili LA, Kroy DC, Lazarus JV, Loomba R, Manns MP, Marchesini G, Nakajima A, Negro F, Petta S, Ratziu V, Romero-Gomez M, Sanyal A, Schattenberg JM, Tacke F, Tanaka J, Trautwein C, Wei L, Zeuzem S, Razavi H. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. *J Hepatol* 2018; **69**: 896-904 [PMID: 29886156 DOI: 10.1016/j.jhep.2018.05.036]

3 **Bargiggia S**, Maconi G, Elli M, Molteni P, Ardizzone S, Parente F, Todaro I, Greco S, Manzionna G, Bianchi Porro G. Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center. *J Clin Gastroenterol* 2003; **36**: 417-420 [PMID: 12702985 DOI: 10.1097/00004836-200305000-00012]

4 **Likhitsup A**, Dundulis J, Ansari S, El-Halawany H, Michelson R, Hutton C, Kennedy K, Helzberg JH, Chhabra R. Prevalence of non-alcoholic fatty liver disease on computed tomography in patients with inflammatory bowel disease visiting an emergency department. *Ann Gastroenterol* 2019; **32**: 283-286 [PMID: 31040626 DOI: 10.20524/aog.2019.0371]

5 **Gaidos JKJ**, Fuchs M. Increased Prevalence of NAFLD in IBD Patients. *Dig Dis Sci* 2017; **62**: 1362 [PMID: 28357696 DOI: 10.1007/s10620-017-4552-8]

6 **Yki-Järvinen H**. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. *Lancet Diabetes Endocrinol* 2014; **2**: 901-910 [PMID: 24731669 DOI: 10.1016/S2213-8587(14)70032-4]

7 **Hernaez R**, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, Clark JM. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. *Hepatology* 2011; **54**: 1082-1090 [PMID: 21618575 DOI: 10.1002/hep.24452]

8 **Adams LA**, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. *Gastroenterology* 2005; **129**: 113-121 [PMID: 16012941 DOI: 10.1053/j.gastro.2005.04.014]

9 **Gastaldelli A**, Kozakova M, Højlund K, Flyvbjerg A, Favuzzi A, Mitrakou A, Balkau B; RISC Investigators. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. *Hepatology* 2009; **49**: 1537-1544 [PMID: 19291789 DOI: 10.1002/hep.22845]

10 **Sourianarayanane A**, Garg G, Smith TH, Butt MI, McCullough AJ, Shen B. Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease. *J Crohns Colitis* 2013; **7**: e279-e285 [PMID: 23158500 DOI: 10.1016/j.crohns.2012.10.015]

11 **Likhitsup A**, Dundulis J, Ansari S, Patibandla S, Hutton C, Kennedy K, Helzberg JH, Chhabra R. High prevalence of non-alcoholic fatty liver disease in patients with inflammatory bowel disease receiving anti-tumor necrosis factor therapy. *Ann Gastroenterol* 2019; **32**: 463-468 [PMID: 31474792 DOI: 10.20524/aog.2019.0405]

12 **Adams LC**, Lübbe F, Bressem K, Wagner M, Hamm B, Makowski MR. Non-alcoholic fatty liver disease in underweight patients with inflammatory bowel disease: A case-control study. *PLoS One* 2018; **13**: e0206450 [PMID: 30427909 DOI: 10.1371/journal.pone.0206450]

13 **Xu ZW**, Li YS. Pathogenesis and treatment of parenteral nutrition-associated liver disease. *Hepatobiliary Pancreat Dis Int* 2012; **11**: 586-593 [PMID: 23232629 DOI: 10.1016/s1499-3872(12)60229-x]

14 **Barron LK**, Gayer CP, Roberts A, Golden JM, Aladegbami BG, Guo J, Erwin CR, Warner BW. Liver steatosis induced by small bowel resection is prevented by oral vancomycin. *Surgery* 2016; **160**: 1485-1495 [PMID: 27592213 DOI: 10.1016/j.surg.2016.07.018]

15 **Dourakis SP**, Sevastianos VA, Kaliopi P. Acute severe steatohepatitis related to prednisolone therapy. *Am J Gastroenterol* 2002; **97**: 1074-1075 [PMID: 12003403 DOI: 10.1111/j.1572-0241.2002.05644.x]

16 **Maaser C**, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V, Calabrese E, Baumgart DC, Bettenworth D, Borralho Nunes P, Burisch J, Castiglione F, Eliakim R, Ellul P, González-Lama Y, Gordon H, Halligan S, Katsanos K, Kopylov U, Kotze PG, Krustinš E, Laghi A, Limdi JK, Rieder F, Rimola J, Taylor SA, Tolan D, van Rheenen P, Verstockt B, Stoker J; European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR]. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. *J Crohns Colitis* 2019; **13**: 144-164 [PMID: 30137275 DOI: 10.1093/ecco-jcc/jjy113]

17 **Satsangi J**, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. *Gut* 2006; **55**: 749-753 [PMID: 16698746 DOI: 10.1136/gut.2005.082909]

18 **Harvey RF**, Bradshaw JM. A simple index of Crohn's-disease activity. *Lancet* 1980; **1**: 514 [PMID: 6102236 DOI: 10.1016/s0140-6736(80)92767-1]

19 **Walmsley RS**, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. *Gut* 1998; **43**: 29-32 [PMID: 9771402 DOI: 10.1136/gut.43.1.29]

20 **Saadeh S**, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ. The utility of radiological imaging in nonalcoholic fatty liver disease. *Gastroenterology* 2002; **123**: 745-750 [PMID: 12198701 DOI: 10.1053/gast.2002.35354]

21 **Fousekis FS**, Katsanos KH, Theopistos VI, Baltayiannis G, Kosmidou M, Glantzounis G, Christou L, Tsianos EV, Christodoulou DK. Hepatobiliary and pancreatic manifestations in inflammatory bowel diseases: a referral center study. *BMC Gastroenterol* 2019; **19**: 48 [PMID: 30943899 DOI: 10.1186/s12876-019-0967-3]

22 **Zou ZY**, Shen B, Fan JG. Systematic Review with Meta-analysis: Epidemiology of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease. *Inflamm Bowel Dis* 2019; **25**: 1764-1772 [PMID: 30918952 DOI: 10.1093/ibd/izz043]

23 **Mensink GB**, Schienkiewitz A, Haftenberger M, Lampert T, Ziese T, Scheidt-Nave C. [Overweight and obesity in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1)]. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* 2013; **56**: 786-794 [PMID: 23703499 DOI: 10.1007/s00103-012-1656-3]

24 **Carr RM**, Patel A, Bownik H, Oranu A, Kerner C, Praestgaard A, Forde KA, Reddy KR, Lichtenstein GR. Intestinal Inflammation Does Not Predict Nonalcoholic Fatty Liver Disease Severity in Inflammatory Bowel Disease Patients. *Dig Dis Sci* 2017; **62**: 1354-1361 [PMID: 28265826 DOI: 10.1007/s10620-017-4495-0]

25 **Magrì S**, Paduano D, Chicco F, Cingolani A, Farris C, Delogu G, Tumbarello F, Lai M, Melis A, Casula L, Fantini MC, Usai P. Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: Beyond the natural history. *World J Gastroenterol* 2019; **25**: 5676-5686 [PMID: 31602167 DOI: 10.3748/wjg.v25.i37.5676]

26 **Weidinger C**, Ziegler JF, Letizia M, Schmidt F, Siegmund B. Adipokines and Their Role in Intestinal Inflammation. *Front Immunol* 2018; **9**: 1974 [PMID: 30369924 DOI: 10.3389/fimmu.2018.01974]

27 **Han S**, Wang G, Qiu S, de la Motte C, Wang HQ, Gomez G, Englander EW, Greeley GH Jr. Increased colonic apelin production in rodents with experimental colitis and in humans with IBD. *Regul Pept* 2007; **142**: 131-137 [PMID: 17391779 DOI: 10.1016/j.regpep.2007.02.002]

28 **Ge Y**, Li Y, Chen Q, Zhu W, Zuo L, Guo Z, Gong J, Cao L, Gu L, Li J. Adipokine apelin ameliorates chronic colitis in Il-10-/- mice by promoting intestinal lymphatic functions. *Biochem Pharmacol* 2018; **148**: 202-212 [PMID: 29309764 DOI: 10.1016/j.bcp.2018.01.011]

29 **Wang Y**, Song J, Bian H, Bo J, Lv S, Pan W, Lv X. Apelin promotes hepatic fibrosis through ERK signaling in LX-2 cells. *Mol Cell Biochem* 2019; **460**: 205-215 [PMID: 31270645 DOI: 10.1007/s11010-019-03581-0]

**Footnotes**

**Institutional review board statement:** The study was approved by the Ethics Committee of the University of Heidelberg (protocol number: S-299/2018).

**Conflict-of-interest statement:**Annika Gauss received travel fees from Abbvie and Janssen, speaker’s fees from Janssen, MSD, Tillotts, and Takeda, and consultation fees from Janssen and AMGEN; Peter Hoffmann received travel fees from Abbvie and Janssen and speaker’s fees from Janssen.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** October 12, 2020

**First decision:** October 27, 2020

**Article in press:** November 21, 2020

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Germany

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Park S **S-Editor:** Zhang L **L-Editor:** A **P-Editor:** Liu JH

**Figure Legends**

 

**Figure 1 Flow diagram of inclusion and exclusion.** A: Crohn’s disease patients; B: Ulcerative colitis patients.

**Table 1 Comparison of baseline characteristics between the subgroups of patients with nonalcoholic fatty liver disease versus those without nonalcoholic fatty liver disease in Crohn’s disease**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | **NAFLD (*n* = 145)** | **No NAFLD (*n* = 157)** | ***P* value** |
| Male, *n* (%) | 75 (52) | 74 (47) | 0.495 |
| Age at abdominal ultra sound (yr), median (IQR) | 49.0 (20.0) | 35.0 (19.0) | < 0.001c |
| BMI (kg/m²), median (IQR) | 28.0 (7.6) | 23.0 (4.4) | < 0.001c |
| Diabetes mellitus, *n* (%) | 7 (5) | 1 (1) | 0.057 |
| Dyslipidemia, *n* (%) | 12 (8) | 3 (2) | 0.0131 |
| Hypertension, *n* (%) | 50 (34) | 20 (13) | < 0.001c |
| Current smoking, *n* (%) | 35 (24) | 29 (18) | 0.288 |
| Smoking in the past, *n* (%) | 28 (19) | 31 (20) | 1.000 |
| Smoking in general, *n* (%) | 63 (44) | 60 (38) | 0.420 |
| HBI (IQR), *n* = 217 | 3.0 (5.0) | 1.0 (3.0) | < 0.001c |
| HBI > 4, *n* (%), *n* = 217 | 46 (40) | 15 (15) | < 0.001c |
| Inflammation in colonoscopy, *n* (%), *n* = 83 | 27 (61) | 20 (51) | 0.330 |
| Inflammation in bowel ultrasound, *n* (%), *n* = 101 | 54 (82) | 47 (85) | 0.772 |
| CRP, mg/L (IQR), *n* = 293 | 2.5 (7.0) | 3.0 (7.6) | 0.846 |
| White blood cells, /nl (IQR), *n* = 293 | 7.8 (3.0) | 7.8 (2.8) | 0.737 |
| Fecal calprotectin, µg/g (IQR), *n* = 172 | 111 (230) | 112 (249) | 0.638 |
| γGT, U/l (IQR) | 24.0 (25.0) | 16 .0(16.5) | < 0.001c |
| Elevated transaminases, *n* (%), *n* = 260 | 18 (16) | 9 (6) | 0.069 |
| Disease duration at abdominal ultrasound (yr), median (IQR) | 16.0 (21.0) | 11.0 (12.0) | 0.002b |
| History of bowel resection(s), *n* (%) | 72 (50) | 54 (45) | 0.010a |
| Biological treatment at the time of ultrasound, *n* (%) | 104 (72) | 103 (66) | 0.308 |
| Treatment with adalimumab at the time of ultrasound, *n* (%) | 53 (37) | 57 (36) | 0.767 |
| Treatment with infliximab at the time of ultrasound, *n* (%) | 29 (20) | 21 (13) | 0.164 |
| Treatment with vedolizumab at the time of ultrasound, *n* (%) | 11 (8) | 10 (6) | 0.850 |
| Treatment with ustekinumab at the time of ultrasound, *n* (%) | 14 (10) | 18 (11) | 0.746 |
| Treatment with azathioprine at the time of ultrasound, *n* (%) | 19 (13) | 18 (11) | 0.796 |
| Treatment with budesonide at the time of ultrasound, *n* (%) | 7 (5) | 12 (8) | 0.576 |
| Treatment with systemic steroids < 7.5 mg at the time of ultrasound, *n* (%) | 6 (4) | 8 (5) | 0.903 |
| Treatment with systemic steroids > 7.5 mg at the time of ultrasound, *n* (%) | 10 (7) | 15 (10) | 0.530 |
| Treatment with systemic steroids at the time of ultrasound, *n* (%) | 14 (10) | 21 (13) | 0.407 |
| Treatment with mesalazine at the time of ultrasound, *n* (%) | 25 (17) | 19 (12) | 0.271 |
| Treatment with sulfasalazine at the time of ultrasound, *n* (%) | 13 (9) | 3 (2) | 0.013a |

a*P* < 0.05; b*P* < 0.01; c*P* < 0.001. BMI: Body mass index; CRP: C-reactive protein; γGT: Gamma-glutamyl transferase; HBI: Harvey bradshaw index; IQR: Interquartile range; NAFLD: Nonalcoholic fatty liver disease.

**Table 2 Results from multivariable logistic regression model (backwards elimination) to identify risk factors for nonalcoholic fatty liver disease in Crohn’s disease patients**

|  |  |  |  |
| --- | --- | --- | --- |
| **Parameter** | **Odds ratio** | **95%CI** | ***P* value** |
| Intercept | < 0.01 | < 0.01; < 0.01 | < 0.001c |
| Elevated HBI | 3.80 | 1.75-8.70 | 0.001b |
| Age at abdominal ultrasound (yr) | 1.05 | 1.02-1.08 | < 0.001c |
| BMI (kg/m²) | 1.25 | 1.15-1.37 | < 0.001c |
| History of bowel resection(s) | 1.47 | 0.74-2.92 | 0.274 |
| Hypertension | 0.81 | 0.31-2.09 | 0.668 |
| Current smoking | 1.17 | 0.51-2.69 | 0.707 |
| Dyslipidemia | 3.48 | 0.52-39.13 | 0.245 |

b*P* < 0.01; c*P* < 0.001. BMI: Body mass index; CRP: C-reactive protein; HBI: Harvey Bradshaw Index; OR: Odds ratio; CI: Confidence interval.

**Table 3 Number of abdominal ultrasound examinations per patient**

|  |  |  |
| --- | --- | --- |
| **Ultrasound examinations (*n*)** | **CD patients** | **UC patients** |
| 1 | 119 | 83 |
| 2 | 62 | 50 |
| 3 | 57 | 31 |
| 4 | 53 | 21 |
| 5 | 48 | 14 |
| 6 | 37 | 9 |
| 7 | 24 | 14 |
| 8 | 17 | 17 |
| 9 | 14 | 7 |
| 10 | 4 | 13 |
| 11 | 2 | 3 |
| 12 | 2 | 1 |

CD: Crohn’s disease; UC: Ulcerative colitis.

**Table 4 Results of mixed model analysis to identify factors associated with nonalcoholic fatty liver disease in Crohn’s disease patients**

|  |
| --- |
| **Confounder model** |
| **Variable** | **Estimate** | **95%CI** | ***P* value** |
| Female sex | 0.70 | 0.09-1.31 | 0.293 |
| Age at abdominal ultrasound (in years) | 1.07 | 1.04-1.09 | < 0.001c |
| BMI at abdominal ultrasound (in years) | 1.32 | 1.30-1.34 | < 0.001c |
| Diabetes mellitus | 2.36 | 0.11-4.61 | 0.509 |
| Hypertension | 0.78 | -0.07-1.62 | 0.586 |
| Dyslipidemia | 10.82 | 8.85-12.80 | 0.049a |
| Current smoking | 1.91 | 1.28-2.53 | 0.109 |
| Steroid use | 0.74 | 0.27-1.21 | 0.287 |
| Parameters included in model with age and BMI |  |  |  |
| Elevated HBI | 2.99 | 2.41-3.58 | < 0.001c |
| Inflammation in colonoscopy | 16.40 | 14.59-18.11 | 0.002b |
| Inflammation in bowel ultrasound | 1.46 | 1.30-1.61 | 0.344 |
| Elevated CRP concentration | 1.17 | 1.01-1.33 | 0.502 |
| Elevated white blood cell count | 0.96 | 0.10-1.12 | 0.295 |
| Elevated fecal calprotectin concentration | 1.34 | 1.19-1.50 | 0.455 |
| History of bowel resection(s) | 2.03 | 1.42-2.64 | 0.023a |
| Biologic treatment | 1.01 | 0.85-1.17 | 0.959 |
| Adalimumab treatment  | 1.09 | 0.93-1.25 | 0.709 |
| Infliximab treatment | 1.64 | 1.48-1.79 | 0.135 |
| Vedolizumab treatment | 1.40 | 1.24-1.56 | 0.523 |
| Ustekinumab treatment | 1.13 | 0.01-2.25 | 0.833 |
| Golimumab treatment | 1.34 | 1.19-1.50 | 0.874 |
| Azathioprine therapy | 1.98 | 1.36-2.61 | 0.031a |
| Methotrexate treatment | 1.15 | 0.99-1.30 | 0.843 |
| 6-Mercaptopurine treatment | 1.08 | 0.92-1.24 | 0.940 |
| Sulfasalazine treatment | 0.53 | 0.38-0.69 | 0.310 |
| Mesalazine treatment | 1.14 | 0.98-1.29 | 0.688 |

a*P* < 0.05; b*P* < 0.01; c*P* < 0.001. BMI: Body mass index; CRP: C-reactive protein; HBI: Harvey bradshaw index; CI: Confidence interval.

**Table 5 Comparison of baseline characteristics between the subgroups of patients with nonalcoholic fatty liver disease versus those without nonalcoholic fatty liver disease in ulcerative colitis**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | **NAFLD (*n* = 68)** | **No NAFLD (*n* = 85)** | ***P* value** |
| Male, *n* (%) | 40 (59) | 37 (44) | 0.086 |
| Age at abdominal ultrasound (yr), median (IQR) | 48.5 (18.5) | 37.0 (21.0) | 0.005b |
| BMI (kg/m²), median (IQR) | 28.0 (5.7) | 22.8 (5.3) | < 0.001c |
| Diabetes mellitus, *n* (%) | 6 (9) | 1 (1) | 0.057 |
| Dyslipidemia, *n* (%) | 2 (3) | 2 (2) | 1.000 |
| Hypertension, *n* (%) | 22 (32) | 6 (7) | < 0.001c |
| Current smoking, *n* (%) | 4 (6) | 1 (1) | 0.242 |
| Smoking in the past, *n* (%) | 20 (30) | 11 (13) | 0.021a |
| Smoking in general, *n* (%) | 24 (35) | 12 (14) | 0.004b |
| SCCAI (IQR), *n* = 124 | 2.0 (4.0) | 1.0 (3.0) | 0.253 |
| SCCAI > 4, *n* (%), *n* = 124 | 14 (24) | 9 (14) | 0.156 |
| Inflammation in colonoscopy, *n* (%), *n* = 45 | 15 (60) | 9 (45) | 0.123 |
| Inflammation in bowel ultrasound, *n* (%), *n* = 28 | 10 (91) | 15 (88) | 0.812 |
| CRP, mg/l (IQR), *n* = 146 | 2.9 (8.0) | 1.0 (5.1) | 0.114 |
| White blood cells, /nl (IQR), *n* = 147 | 7.5 (2.9) | 7.0 (3.2) | 0.300 |
| Fecal calprotectin, µg/g (IQR), *n* = 87 | 103 (390) | 147 (359) | 0.612 |
| γGT, U/l (IQR) | 23.0 (40.0) | 18.0 (25.0) | 0.007b |
| Elevated transaminases, *n* (%), *n* = 147 | 8 (13) | 7 (8) | 0.387 |
| Disease duration at abdominal ultrasound (yr), median (IQR) | 9.0 (12.5) | 10.0 (30.5) | 0.408 |
| History of bowel resection(s), *n* (%) | 6 (9) | 12 (14) | 0.449 |
| Biological treatment at the time of ultrasound, *n* (%) | 33 (49) | 52 (61) | 0.161 |
| Treatment with adalimumab at the time of ultrasound, *n* (%) | 8 (12) | 13 (15) | 0.694 |
| Treatment with infliximab at the time of ultrasound, *n* (%) | 7 (10) | 20 (24) | 0.055 |
| Treatment with vedolizumab at the time of ultrasound, *n* (%) | 19 (28) | 19 (22) | 0.544 |
| Treatment with azathioprine at the time of ultrasound, *n* (%) | 13 (19) | 14 (16) | 0.831 |
| Treatment with budesonide at the time of ultrasound, *n* (%) | 3 (4) | 3 (4) | 1.000 |
| Treatment with systemic steroids < 7.5 mg at the time of ultrasound, *n* (%) | 7 (10) | 5 (6) | 0.480 |
| Treatment with systemic steroids > 7.5 mg at the time of ultrasound, *n* (%) | 10 (15) | 12 (14) | 1.000 |
| Treatment with systemic steroids at the time of ultrasound, *n* (%) | 13 (19) | 16 (19) | 1.000 |
| Treatment with mesalazine at the time of ultrasound, *n* (%) | 42 (62) | 42 (49) | 0.173 |
| Treatment with sulfasalazine at the time of ultrasound, *n* (%) | 2 (3) | 5 (6) | 0.634 |

a*P* < 0.05; b*P* < 0.01; c*P* < 0.001. BMI: Body mass index; CRP: C-reactive protein; γGT: Gamma-glutamyl transferase; IQR: Interquartile range; NAFLD: Nonalcoholic fatty liver disease; SCCAI: Simple Clinical Colitis Activity Index.

**Table 6 Results from multivariable logistic regression model (backwards elimination) to identify risk factors for nonalcoholic fatty liver disease in ulcerative colitis patients**

|  |  |  |  |
| --- | --- | --- | --- |
| **Parameter** | **Odds ratio** | **95%CI** | ***P* value** |
| Intercept | < 0.01 | < 0.01; < 0.01 | < 0.001c |
| Age at abdominal ultrasound (yr) | 1.01 | 0.98-1.04 | 0.689 |
| BMI (kg/m²) | 1.25 | 1.14-1.38 | < 0.001c |
| Hypertension | 3.01 | 0.99-10.04 | 0.058 |
| Adalimumab therapy | 2.10 | 0.68-7.20 | 0.213 |

c*P* < 0.001. BMI: Body mass index; OR: Odds ratio; CI: Confidence interval.

**Table 7 Results of mixed model analysis to identify factors associated with nonalcoholic fatty liver disease in ulcerative colitis patients**

|  |
| --- |
| **Confounder model** |
| **Variable** | **Estimate** | **95%CI** | ***P* value** |
| Female sex | 0.62 | 0.50-0.65 | 0.159 |
| Age at ultrasound (in years) | 0.99 | 0.98-1.03 | 0.637 |
| BMI at ultrasound (in years) | 1.28 | 0.71-1.85 | < 0.001c |
| Diabetes mellitus | 2.14 | 0.95-4.79 | 0.441 |
| Hypertension | 2.89 | 2.51-4.10 | 0.037a |
| Dyslipidemia | 1.46 | 0.98-2.84 | 0.695 |
| Current smoking | 1.77 | 1.26-2.40 | 0.525 |
| Steroid use | 0.88 | 0.20-1.54 | 0.652 |
| Parameters included in model with age and BMI |  |  |  |
| Elevated SCCAI | 1.58 | 1.42-1.74 | 0.145 |
| Inflammation in colonoscopy | 3.60 | 2.69-4.50 | 0.005b |
| Inflammation in bowel ultrasound | 2.31 | 2.16-2.47 | 0.162 |
| Elevated CRP concentration | 0.99 | 0.83-1.14 | 0.959 |
| Elevated white blood cell count | 1.01 | 0.85-1.17 | 0.782 |
| Elevated fecal calprotectin concentration | 1.06 | 0.90-1.22 | 0.923 |
| History of bowel resection(s) | 1.66 | 1.50-1.82 | 0.332 |
| Biologic treatment | 0.69 | 0.53-0.85 | 0.167 |
| Adalimumab treatment | 0.74 | 0.58-0.90 | 0.426 |
| Infliximab treatment | 0.77 | 0.62-0.93 | 0.484 |
| Vedolizumab treatment | 1.14 | 0.98-1.30 | 0.739 |
| Ustekinumab treatment | 0.19 | 0.03-0.35 | 0.407 |
| Golimumab treatment | 1.14 | 0.98-1.30 | 0.892 |
| Azathioprine therapy | 1.19 | 1.03-1.35 | 0.597 |
| Methotrexate treatment | 1.50 | 1.34-1.66 | 0.734 |
| 6-Mercaptopurine treatment | 0.94 | 0.79-1.10 | 0.947 |
| Sulfasalazine treatment | 1.43 | 1.27-1.58 | 0.491 |
| Mesalazine treatment | 0.88 | -0.25-2.00 | 0.635 |

a*P* < 0.05; b*P* < 0.01; c*P* < 0.001. BMI: Body mass index; CRP: C-reactive protein; SCCAI: Simple Clinical Colitis Activity Index; CI: Confidence interval.